ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling
Stefanie Schmidt, Neele Schumacher, Jeanette Schwarz, Simone Tangermann, Lukas Kenner, Michaela Schlederer, Maria Sibilia, Markus Linder, Annelore Altendorf-Hofmann, Thomas Knoesel, Elisabeth S Gruber, Georg Oberhuber, Julia Bolik, Ateequr Rehman, Anupam Sinha, Juliane Lokau, Philipp Arnold, Anne-Sophie Cabron, Friederike Zunke, Christoph Becker-Pauly Show all
Journal of Experimental Medicine | ROCKEFELLER UNIV PRESS | Published : 2018
Awarded by Deutsche Forschungsgemeinschaft, Bonn
Awarded by Austrian Science Fund
Awarded by European Research Council
Awarded by National Breast Cancer Foundation
This work was supported by the Deutsche Forschungsgemeinschaft, Bonn (CRC841, project C1 to D. Schmidt-Arras and S. Rose-John; CRC877, project A1 to S. Rose-John; SFB877, project A9 to C. Becker-Pauly; project A10 to C. Garbers; SFB877, project B9 to P. Rosenstiel; and the Cluster of Excellence "Inflammation at Interfaces"). The research of M. Sibilia was supported by Austrian Science Fund grant DK W1212 and the European Research Council Advanced Grant 694883.